This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Polatuzumab vedotin parenteral

Updated 2 Feb 2023 | Polatuzumab vedotin


Infusions of polatuzumab vedotin.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • polatuzumab vedotin 140mg powder for concentrate for soln for infusion vial
  • polatuzumab vedotin 30mg powder for concentrate for soln for infusion vial
  • POLIVY 140mg powder for concentrate for soln for infusion vial
  • POLIVY 30mg powder for concentrate for soln for infusion vial
  • Therapeutic Indications


    Large B-cell lymphoma

    Treatment in combination with bendamustine and rituximab of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for whom haematopoietic stem cell transplant is not suitable.


    Due to the complexity and specialist nature of dosage regimens for the treatment of malignant disease, specific dosing information on this agent is not included.
    Doses may vary significantly if this agent is used as monotherapy or different combinations.
    When using this agent, specialist literature, national guidelines, cancer network protocols and Trust chemotherapy protocols should be consulted.

    Additional Dosage Information

    Dose modification for peripheral neuropathy (PN)
    In case of severity Grade 2 or 3, polatuzumab should be withhold until resolved to Grade 0 or 1. If recovered to Grade 1 or less on or before day 14, restart polatuzumab at a permanently reduced dose of 1.4mg/Kg.

    Discontinue polatuzumab in case of a previous dose reduction or no recovering to Grade 0 or 1 on or before day 14.


    Polatuzumab vedotin is for intravenous use.

    Polatuzumab vedotin should not be administered as intravenous push or bolus.


    Children under 18 years
    Severe infection
    Moderate hepatic impairment
    Renal impairment - creatinine clearance below 30 ml/minute

    Precautions and Warnings

    Females of childbearing potential
    Hepatic disorder
    Peripheral neuropathy
    Positive HIV status

    Administration of live vaccines is not recommended
    Appropriate antibiotic therapy required in presence or if risk of infection
    Consider pre-medication with antihistamines and/or antipyretics
    Give pre-treatment counselling and consideration of sperm cryopreservation
    Maintain adequate hydration of patient prior / during treatment
    Prophylactic G-CSF should be considered
    Concentrate must be diluted and used as an infusion
    Consult local policy on the safe use of anti-cancer drugs
    Do not mix with other drugs or substances
    For single use only
    Record name and batch number of administered product
    Reduce infusion rate if mild to moderate infusion reaction occurs
    Staff: Not to be handled by pregnant staff
    Treatment to be administered under the supervision of a specialist
    Exclude pregnancy prior to initiation of treatment
    May cause activation / exacerbation of latent / intercurrent infections
    Monitor closely any patient who develops new infection while on treatment
    Monitor complete blood counts before each dose
    Monitor for symptoms of peripheral neuropathy
    Monitor levels of hepatic enzymes and bilirubin
    Monitor patient closely for serious adverse events following administration
    Monitor patients for signs of tumour lysis syndrome
    Advise patient to report unexplained fever, sore throat, bruising, bleeding
    Consider discontinuing treatment if serious infection occurs
    Consider dose reduction/stopping if new/worsening peripheral neuropathy
    Discontinue if Progressive multifocal leukoencephalopathy (PML) develops
    Discontinue permanently if life threatening infusion reactions occur
    Interrupt treatment if severe infusion reaction occurs
    Suspend treatment and/or reduce dose for grade 3 thrombocytopenia
    Suspend treatment if grade 3 neutropenia occurs
    Advise patient not to take St John's wort concurrently
    Female: Contraception required during and for 9 months after treatment
    Male: Contraception required during and for 6 months after treatment
    Breastfeeding: Do not breastfeed during & for 3 months after treatment
    Driving or operating machinery not advisable following treatment

    Infusion-related reactions (IRR)
    The initial dose of polatuzumab vedotin should be administered as a 90-minute intravenous infusion. Patients should be monitored for infusion-related and hypersensitivity reactions during the infusion and for at least 90 minutes following completion of the initial dose.

    Discontinue permanently infusion if first time in presence of wheezing, bronchospasm and generalized urticaria (Grade 3 reactions). Also, discontinue permanently in case of recurrent Grade 2 wheezing and urticaria or any other recurrent Grade 3 symptoms.

    Infusion may be restarted at 50% of the rate achieved prior to interruption in cases of complete resolution of symptoms. In the absence of infusion-related symptoms, the rate of infusion may be escalated in increments of 50mg/hour.

    If the initial infusion was well tolerated, the subsequent dose of polatuzumab vedotin may be administered as a 30-minute infusion and patients should be monitored during the infusion and for at least 30 minutes after completion of the infusion. Administer premedication for all cycles.

    Progressive Multifocal Leukoencephalopathy Syndrome (PML)
    Progressive multifocal leukoencephalopathy syndrome (PML) has been reported in some patients treated with this agent. If patients present with symptoms indicating PML such as worsening neurological, cognitive or behavioural signs or symptoms, an MRI should be performed. Polatuzumab vedotin and any concomitant chemotherapy should be withheld if PML is suspected. If PML is diagnosed, treatment should be permanently discontinued.

    Tumour lysis syndrome (TLS)
    Patients with high tumour burden and rapidly proliferative tumour may be at increased risk of TLS. Appropriate measures and prophylaxis in accordance with local guidelines should be taken prior to treatment with polatuzumab vedotin.

    Pregnancy and Lactation


    Polatuzumab vedotin is contraindicated during pregnancy.

    The manufacturer does not recommend the use of polatuzumab vedotin during pregnancy and in women of childbearing potential not using contraception unless the potential benefit outweighs the potential risk to the foetus.

    There are no data in pregnant women using polatuzumab vedotin. Animal studies have shown reproductive toxicity. Based on the mechanism of action and nonclinical studies, polatuzumab vedotin can be harmful to the foetus when administered to a pregnant woman.


    Polatuzumab vedotin is contraindicated during breastfeeding.

    The manufacturer recommends discontinuing breastfeeding during treatment with polatuzumab vedotin for at least 3 months after the last dose.

    It is not known whether polatuzumab vedotin or its metabolites are excreted in human breast milk. A risk for breast feeding children cannot be excluded.

    Side Effects

    Abdominal pain
    Blurred vision
    Cytomegalovirus infection
    Decreased appetite
    Elevated serum lipase
    Febrile neutropenia
    Gait abnormality
    Herpes infections
    Increase of liver transaminases
    Infusion-related symptoms
    Peripheral neuropathy
    Peripheral sensory neuropathy
    Progressive multifocal leukoencephalopathy (PML)
    Tumour lysis syndrome
    Upper abdominal pain
    Upper respiratory tract infection
    Weight loss


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2021

    Reference Sources

    Summary of Product Characteristics: Polivy 140mg powder for concentrate for solution for infusion. Roche Products Limited. Revised December 2020.

    Summary of Product Characteristics: Polivy 30mg powder for concentrate for solution for infusion. Roche Products Limited. Revised December 2020.

    NICE Evidence Services Available at: Last accessed: 18 March 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.